Open access
Open access
Powered by Google Translator Translator

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

18 Aug, 2021 | 09:04h | UTC

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination – The Lancet


RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)


Commentary on Twitter (thread – click for more)


Stay Updated in Your Specialty

No spam, just news.